title: PML/RAR alpha APL with undifferentiated morphology and stem cell immunophenotype.
authors.forename: R
authors.initials: R
authors.lastname: Foley
authors.forename: P
authors.initials: P
authors.lastname: Soamboonsrup
authors.forename: T
authors.initials: T
authors.lastname: Kouroukis
authors.forename: B
authors.initials: B
authors.lastname: Leber
authors.forename: R F
authors.initials: RF
authors.lastname: Carter
authors.forename: L
authors.initials: L
authors.lastname: Sunisloe
authors.forename: K
authors.initials: K
authors.lastname: Chorneyko
authors.forename: P B
authors.initials: PB
authors.lastname: Neame
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002884:Chromosomes, Human, Pair 15 / Q000235:genetics*; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D006801:Humans; D016130:Immunophenotyping; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D015514:Oncogene Proteins, Fusion / Q000032:analysis*; D013234:Stem Cells; D014178:Translocation, Genetic / Q000235:genetics*
chemical_list: D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein